Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer

Lund, Sweden — 17 February 2026 — Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed as Camurus’ Chief Corporate Development Officer (CCDO) and member of the executive management team, effective 23 March, 2026.

Jane brings more than 20 years of experience from senior positions at Novo Nordisk and AstraZeneca within Business and Corporate Development, with a strong track record of driving strategic licensing and M&A transactions, integration processes and alliance management. Most recently, she had the position as Corporate VP in Global Business Development at Novo Nordisk. Jane holds a PhD in Organic & Medicinal chemistry from the Technical University of Denmark (DTU) and the University of Kansas, US, and has a background as senior scientist.

“We are pleased to welcome Jane Buus Laursen to Camurus as Chief Corporate Development Officer. Jane will have a central role in the company with responsibility for strategic development towards new growth targets, expansion and long-term value creation, together with the executive management”, says Fredrik Tiberg, Camurus' President and CEO. “Jane offers significant experience from senior positions at leading pharmaceutical companies and joins Camurus during ongoing growth and expansion.”

“I am excited to join Camurus at a pivotal point of its growth, with strong momentum and opportunity ahead. I am highly motivated by the strong science-driven and agile culture and clear focus on improving patients’ lives. I look forward to working closely with Fredrik, the executive management, and colleagues across the organization, to develop and implement Camurus’ strategic priorities for long-term growth”, says Jane Buus Laursen.

About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal^® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
[email protected]
 

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
[email protected]
 

This information was submitted for publication at 8:00 am CET on 17 February 2026.